In re: COVIDIEN HERNIA MESH PRODUCTS LIABILITY LITIGATION; Larry Patterson and Tammy Patterson v. COVIDIEN, INC., et al.

CourtDistrict Court, D. Massachusetts
DecidedFebruary 26, 2026
Docket1:22-cv-10153
StatusUnknown

This text of In re: COVIDIEN HERNIA MESH PRODUCTS LIABILITY LITIGATION; Larry Patterson and Tammy Patterson v. COVIDIEN, INC., et al. (In re: COVIDIEN HERNIA MESH PRODUCTS LIABILITY LITIGATION; Larry Patterson and Tammy Patterson v. COVIDIEN, INC., et al.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re: COVIDIEN HERNIA MESH PRODUCTS LIABILITY LITIGATION; Larry Patterson and Tammy Patterson v. COVIDIEN, INC., et al., (D. Mass. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ___________________________________ ) IN RE: COVIDIEN HERNIA MESH ) PRODUCTS LIABILITY LITIGATION ) MDL NO. II, ) No. 22-md-03029-PBS __________________________________ ) ) LARRY PATTERSON and TAMMY ) PATTERSON, ) ) Plaintiffs, ) ) Civil Action v. ) No. 22-cv-10153-PBS ) COVIDIEN, INC., et al., ) ) Defendants. ) )

ORDER February 26, 2026 Saris, J. Defendants Covidien LP and Sofradim Production SAS (together, “Covidien”) move to strike the declaration of Dr. Lucian Newman III and briefing in reliance on this declaration submitted by Plaintiffs Larry and Tammy Patterson in opposition to Covidien’s motion for summary judgment and motion to exclude the expert testimony of Dr. Stephen Ferzoco. Covidien argues that Plaintiffs failed to disclose Dr. Newman’s declaration before the close of discovery, that the declaration offers expert testimony even though Dr. Newman was not disclosed as an expert, and that the declaration is a sham affidavit. After hearing, the Court denies Covidien’s motion to strike. Covidien first argues that Dr. Newman’s declaration should be

stricken because its production after the close of discovery violates the Court’s scheduling orders. So long as a witness is properly disclosed under Federal Rule of Civil Procedure 26, however, a party may obtain an affidavit or declaration from that witness to support or oppose summary judgment without having previously produced that document to the opposing side during discovery. See, e.g., Frosch v. Alsobrook, No. 24-40662, 2025 WL 1566587, at *2 (5th Cir. June 3, 2025) (per curiam); Benoit v. City of Lake City, 343 F. Supp. 3d 1219, 1223-24 (M.D. Fla. 2018); Brantley v. Ferrell Elec., Inc., 112 F. Supp. 3d 1348, 1357 (S.D. Ga. 2015); Russo v. Estée Lauder Corp., 856 F. Supp. 2d 437, 447 n.4 (E.D.N.Y. 2012); Rivot-Sanchez v. Warner Chilcott Co., 707 F.

Supp. 2d 234, 259 (D.P.R. 2010); Dupee v. Klaff’s, Inc., 462 F. Supp. 2d 233, 235 n.2 (D. Conn. 2006); SEC v. Poirier, 140 F. Supp. 2d 1033, 1041-42 (D. Ariz. 2001). Plaintiffs’ failure to produce Dr. Newman’s declaration during discovery does not justify disregarding that declaration at the summary judgment stage. Nor is exclusion of Dr. Newman’s declaration warranted on the basis that Plaintiffs did not timely disclose Dr. Newman as an expert witness under Rule 26. See Fed. R. Civ. P. 26(a)(2) (listing disclosure requirements for witnesses offering expert testimony). “[A] treating physician, testifying as to his consultation with or treatment of a patient, is not an expert witness for purposes of Rule 26.” Gomez v. Rivera Rodriguez, 344 F.3d 103, 113 (1st Cir.

2003). In his declaration, Dr. Newman asserts in relevant part that he would not have used the Symbotex mesh for Mr. Patterson’s hernia repair had he known “that the collagen barrier could be resorbed within seven days or anything substantially less than thirty days.” Dkt. 95-12 ¶ 9. This assertion is based on his treatment of Mr. Patterson and, thus, is not expert testimony requiring disclosure under Rule 26. See In re C.R. Bard, Inc., 948 F. Supp. 2d 589, 616-17 (S.D. W. Va. 2013) (deeming treating physicians’ testimony about whether they “would have used the . . . products if they were given the warnings that the plaintiffs contend should have been given” to be “fact testimony”); In re Levaquin Prods. Liab. Litig., 726 F. Supp. 2d 1025, 1036 n.4

(D. Minn. 2010) (deeming a treating physician’s “responses to hypothetical questions about what he would have done if he had received adequate warnings” to be lay witness opinions). Finally, Dr. Newman’s declaration does not violate the sham affidavit rule. That rule provides that “where a party has given clear answers to unambiguous questions in discovery, that party cannot create a conflict and resist summary judgment with an affidavit that is clearly contradictory unless there is a satisfactory explanation of why the testimony has changed.” Calderón-Amézquita v. Rivera-Cruz, 158 F.4th 54, 74 (1st Cir. 2025) (quoting Escribano-Reyes v. Pro. Hepa Certificate Corp., 817 F.3d 380, 386 (1st Cir. 2016)). The First Circuit has applied the sham

affidavit rule to an “interested” non-party witness on at least one occasion. Torres v. E.I. Dupont De Nemours & Co., 219 F.3d 13, 16, 20-21 (1st Cir. 2000) (quoting Colantuoni v. Alfred Calcagni & Sons, Inc., 44 F.3d 1, 4 (1st Cir. 1994)) (affirming the striking of an affidavit of the plaintiffs’ client), while the Third Circuit has affirmed a decision to strike a treating physician’s affidavit on this basis, see In re Avandia Mktg., Sales Pracs. & Prods. Liab. Litig., 639 F. App’x 874, 877-78 (3d Cir. 2016). The Court need not decide whether the sham affidavit rule applies to Dr. Newman because, even if it does, the rule does not support striking his declaration. Most of Dr. Newman’s declaration does not clearly contradict his deposition testimony. The only

clear contradiction -- whether, looking back, Dr. Newman would still use Symbotex for Mr. Patterson’s procedure -- is readily explained by Dr. Newman’s post-deposition review of evidence indicating that Symbotex’s collagen barrier may resorb within seven days. See Hernandez-Loring v. Universidad Metropolitana, 233 F.3d 49, 54 (1st Cir. 2000) (“[N]ew sources of information . . . can often explain a revision of testimony.”). While Dr. Newman’s declaration “[c]learly . . . serves as a direct rebuttal to the arguments and theories presented by [Covidien] in [its] summary judgment motion,” the Court cannot strike the declaration solely on that basis without identifying a clear and inadequately explained contradiction with earlier testimony. Selfridge v. Jama,

172 F. Supp. 3d 397, 413 (D. Mass. 2016). Accordingly, Covidien’s motion to strike (Dkt. 104) is DENIED.

SO ORDERED. /s/ PATTI B. SARIS__________ Hon. Patti B. Saris United States District Judge

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Colantuoni v. Alfred Calcagni & Sons, Inc.
44 F.3d 1 (First Circuit, 1994)
Torres v. E.I. DuPont De Nemours & Co.
219 F.3d 13 (First Circuit, 2000)
Hernandez-Loring v. Universidad Metropolitana
233 F.3d 49 (First Circuit, 2000)
Gomez-Candelaria v. Rivera-Rodriguez
344 F.3d 103 (First Circuit, 2003)
Dupee v. Klaff's, Inc.
462 F. Supp. 2d 233 (D. Connecticut, 2006)
Securities & Exchange Commission v. Poirier
140 F. Supp. 2d 1033 (D. Arizona, 2001)
In Re Levaquin Products Liability Litigation
726 F. Supp. 2d 1025 (D. Minnesota, 2010)
Rivot-Sanchez v. Warner Chilcott Co., Inc.
707 F. Supp. 2d 234 (D. Puerto Rico, 2010)
Brantley v. Ferrell Electric, Inc.
112 F. Supp. 3d 1348 (S.D. Georgia, 2015)
Selfridge v. Jama
172 F. Supp. 3d 397 (D. Massachusetts, 2016)
Benoit v. City of Lake City
343 F. Supp. 3d 1219 (M.D. Florida, 2018)
Russo v. Estée Lauder Corp.
856 F. Supp. 2d 437 (E.D. New York, 2012)
In re C.R. Bard, Inc.
948 F. Supp. 2d 589 (S.D. West Virginia, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
In re: COVIDIEN HERNIA MESH PRODUCTS LIABILITY LITIGATION; Larry Patterson and Tammy Patterson v. COVIDIEN, INC., et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-covidien-hernia-mesh-products-liability-litigation-larry-patterson-mad-2026.